Preclinical toxicity and efficacy testing of RiVax, a recombinant protein vaccine against ricin.

@article{Smallshaw2005PreclinicalTA,
  title={Preclinical toxicity and efficacy testing of RiVax, a recombinant protein vaccine against ricin.},
  author={Joan E. Smallshaw and J. A. Richardson and S. J. Pincus and John D Schindler and Ellen S. Vitetta},
  journal={Vaccine},
  year={2005},
  volume={23 39},
  pages={
          4775-84
        }
}
Ricin toxin is a plant-derived ribosome inactivating protein (RIP) of extraordinary toxicity. Vaccination using ricin toxoid or its A chain (RTA) is protective in animals but both vaccines have two potential toxicities, RIP and vascular leak syndrome (VLS). Previously we described three recombinant RTA constructs from which both toxicities were eliminated by site-specific mutations. One mutant, V76M/Y80A, RiVax, has now been further characterized for immunogenicity and toxicity in animals. We… CONTINUE READING
BETA

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 28 CITATIONS

Similar Papers

Loading similar papers…